These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

780 related articles for article (PubMed ID: 27129168)

  • 1. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
    Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
    Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
    Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
    Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
    Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
    Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting.
    Adamczyk A; Niemiec J; Janecka A; Harazin-Lechowska A; Ambicka A; Grela-Wojewoda A; Domagała-Haduch M; Cedrych I; Majchrzyk K; Kruczak A; Ryś J; Jakubowicz J
    Pol J Pathol; 2015 Jun; 66(2):133-41. PubMed ID: 26247526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
    Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
    J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between Mutation and Expression of
    Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
    Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
    Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
    Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
    Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
    J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
    Loi S; Michiels S; Lambrechts D; Fumagalli D; Claes B; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Piccart MJ; Joensuu H; Sotiriou C
    J Natl Cancer Inst; 2013 Jul; 105(13):960-7. PubMed ID: 23739063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
    Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
    Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.
    Levva S; Kotoula V; Kostopoulos I; Manousou K; Papadimitriou C; Papadopoulou K; Lakis S; Koukoulias K; Karavasilis V; Pentheroudakis G; Balassi E; Zagouri F; Kaklamanos IG; Pectasides D; Razis E; Aravantinos G; Papakostas P; Bafaloukos D; Rallis G; Gogas H; Fountzilas G
    Cancer Genomics Proteomics; 2017; 14(3):181-195. PubMed ID: 28446533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
    Cancer Sci; 2015 Nov; 106(11):1582-9. PubMed ID: 26353837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
    Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
    JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.
    Bae SY; Nam SJ; Jung Y; Lee SB; Park BW; Lim W; Jung SH; Yang HW; Jung SP
    Breast Cancer Res Treat; 2018 Nov; 172(2):437-444. PubMed ID: 30132220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasonic Features and Molecular Subtype Predict Somatic Mutations in TP53 and PIK3CA Genes in Breast Cancer.
    Huang Y; Qiang Y; Jian L; Jin Z; Lang Q; Sheng C; Shichong Z; Cai C
    Acad Radiol; 2022 Dec; 29(12):e261-e270. PubMed ID: 35450798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
    Glück S; Ross JS; Royce M; McKenna EF; Perou CM; Avisar E; Wu L
    Breast Cancer Res Treat; 2012 Apr; 132(3):781-91. PubMed ID: 21373875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.